Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1989 Oct;84(4):1220–1225. doi: 10.1172/JCI114288

Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK.

R A Liddle 1, B J Gertz 1, S Kanayama 1, L Beccaria 1, L D Coker 1, T A Turnbull 1, E T Morita 1
PMCID: PMC329781  PMID: 2794058

Abstract

To explore the physiology of cholecystokinin (CCK) in humans, we investigated the effect on gallbladder contraction and gastric emptying of a recently developed CCK receptor antagonist, MK-329. In a double-blind, four-period crossover study eight subjects received single doses of 0.5, 2, or 10 mg MK-329, or placebo, followed by an intravenous infusion of CCK-8 (30 pmol/kg.h). In placebo-treated subjects gallbladder volumes decreased on average to 43% of initial volumes after 2 h of CCK infusion. MK-329 caused a dose-dependent inhibition of CCK-stimulated gallbladder contraction with 10 mg producing complete blockade (P less than 0.01, cf. placebo). Gallbladder contraction and gastric emptying rates after a mixed meal were then measured in a two-period crossover study. Subjects received placebo or 10 mg of MK-329 2 h before eating. Gastric emptying of both solids and liquids was measured simultaneously by gamma scintigraphy. In placebo-treated subjects plasma CCK levels increased postprandially to 2.3 pM, gallbladder volumes decreased 68.4 +/- 3.8% (SE), and the times for 50% emptying of liquids and solids from the stomach were 58 +/- 10 and 128 +/- 8 min, respectively. In MK-329-treated subjects there was a marked elevation in peak CCK levels to 13.8 pM (P less than 0.01, cf. placebo), and gallbladder contraction was completely inhibited. Solid and liquid emptying rates were unaffected. These findings demonstrate that (a) MK-329 is a potent, orally active antagonist of CCK in humans, and (b) CCK is the major regulator of postprandial gallbladder contraction. These data also support the concept of negative feedback regulation of CCK secretion and suggest that mechanisms other than CCK play a dominant role in the regulation of postprandial gastric emptying rates.

Full text

PDF
1220

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chang R. S., Lotti V. J. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4923–4926. doi: 10.1073/pnas.83.13.4923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Christian P. E., Datz F. L., Sorenson J. A., Taylor A. Technical factors in gastric emptying studies. J Nucl Med. 1983 Mar;24(3):264–268. [PubMed] [Google Scholar]
  3. Cox K. L., Rosenquist G. L., Iwahashi-Hosoda C. K. Noncholecystokinin peptides in human serum which cause gallbladder contraction. Life Sci. 1982 Dec 27;31(26):3023–3029. doi: 10.1016/0024-3205(82)90070-4. [DOI] [PubMed] [Google Scholar]
  4. Evans B. E., Bock M. G., Rittle K. E., DiPardo R. M., Whitter W. L., Veber D. F., Anderson P. S., Freidinger R. M. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4918–4922. doi: 10.1073/pnas.83.13.4918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Everson G. T., Braverman D. Z., Johnson M. L., Kern F., Jr A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction. Gastroenterology. 1980 Jul;79(1):40–46. [PubMed] [Google Scholar]
  6. GRIZZLE J. E. THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS. Biometrics. 1965 Jun;21:467–480. [PubMed] [Google Scholar]
  7. Gomez G., Upp J. R., Jr, Lluis F., Alexander R. W., Poston G. J., Greeley G. H., Jr, Thompson J. C. Regulation of the release of cholecystokinin by bile salts in dogs and humans. Gastroenterology. 1988 Apr;94(4):1036–1046. doi: 10.1016/0016-5085(88)90564-1. [DOI] [PubMed] [Google Scholar]
  8. Green G. M., Lyman R. L. Feedback regulation of pancreatic enzyme secretion as a mechanism for trypsin inhibitor-induced hypersecretion in rats. Proc Soc Exp Biol Med. 1972 May;140(1):6–12. doi: 10.3181/00379727-140-36384. [DOI] [PubMed] [Google Scholar]
  9. Green T., Dimaline R., Peikin S., Dockray G. J. Action of the cholecystokinin antagonist L364,718 on gastric emptying in the rat. Am J Physiol. 1988 Nov;255(5 Pt 1):G685–G689. doi: 10.1152/ajpgi.1988.255.5.G685. [DOI] [PubMed] [Google Scholar]
  10. Hashimura E., Shimizu F., Nishino T., Imagawa K., Tateishi K., Hamaoka T. Production of rabbit antibody specific for amino-terminal residues of cholecystokinin octapeptide (CCK-8) by selective suppression of cross-reactive antibody response. J Immunol Methods. 1982 Dec 30;55(3):375–387. doi: 10.1016/0022-1759(82)90097-7. [DOI] [PubMed] [Google Scholar]
  11. Himeno S., Tarui S., Kanayama S., Kuroshima T., Shinomura Y., Hayashi C., Tateishi K., Imagawa K., Hashimura E., Hamaoka T. Plasma cholecystokinin responses after ingestion of liquid meal and intraduodenal infusion of fat, amino acids, or hydrochloric acid in man: analysis with region specific radioimmunoassay. Am J Gastroenterol. 1983 Nov;78(11):703–707. [PubMed] [Google Scholar]
  12. JOHNSON L. P., MAGEE D. F. CHOLECYSTOKININ-PANCREOZYMIN EXTRACTS AND GASTRIC MOTOR INHIBITION. Surg Gynecol Obstet. 1965 Sep;121:557–562. [PubMed] [Google Scholar]
  13. Kanayama S., Himeno S., Higashimoto Y., Yamasaki Y., Kitani T., Tarui S. Plasma cholecystokinin-octapeptide like immunoreactivity in patients with hepatic cirrhosis. Life Sci. 1987 Oct 19;41(16):1915–1920. doi: 10.1016/0024-3205(87)90743-0. [DOI] [PubMed] [Google Scholar]
  14. Kleibeuker J. H., Beekhuis H., Jansen J. B., Piers D. A., Lamers C. B. Cholecystokinin is a physiological hormonal mediator of fat-induced inhibition of gastric emptying in man. Eur J Clin Invest. 1988 Apr;18(2):173–177. doi: 10.1111/j.1365-2362.1988.tb02409.x. [DOI] [PubMed] [Google Scholar]
  15. Krawisz B. R., Miller L. J., DiMagno E. P., Go V. L. In the absence of nutrients, pancreatic-biliary secretions in the jejunum do not exert feedback control of human pancreatic or gastric function. J Lab Clin Med. 1980 Jan;95(1):13–18. [PubMed] [Google Scholar]
  16. Levan V. H., Liddle R. A., Green G. M. Jejunal bypass stimulation of pancreatic growth and cholecystokinin secretion in rats: importance of luminal nutrients. Gut. 1987;28 (Suppl):25–29. doi: 10.1136/gut.28.suppl.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Liddle R. A., Goldfine I. D., Rosen M. S., Taplitz R. A., Williams J. A. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest. 1985 Apr;75(4):1144–1152. doi: 10.1172/JCI111809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Liddle R. A., Green G. M., Conrad C. K., Williams J. A. Proteins but not amino acids, carbohydrates, or fats stimulate cholecystokinin secretion in the rat. Am J Physiol. 1986 Aug;251(2 Pt 1):G243–G248. doi: 10.1152/ajpgi.1986.251.2.G243. [DOI] [PubMed] [Google Scholar]
  19. Liddle R. A., Morita E. T., Conrad C. K., Williams J. A. Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest. 1986 Mar;77(3):992–996. doi: 10.1172/JCI112401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lotti V. J., Cerino D. J., Kling P. J., Change R. S. A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and durations of action of nonpeptide antagonists. Life Sci. 1986 Nov 3;39(18):1631–1638. doi: 10.1016/0024-3205(86)90159-1. [DOI] [PubMed] [Google Scholar]
  21. Lotti V. J., Pendleton R. G., Gould R. J., Hanson H. M., Chang R. S., Clineschmidt B. V. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther. 1987 Apr;241(1):103–109. [PubMed] [Google Scholar]
  22. Owyang C., Louie D. S., Tatum D. Feedback regulation of pancreatic enzyme secretion. Suppression of cholecystokinin release by trypsin. J Clin Invest. 1986 Jun;77(6):2042–2047. doi: 10.1172/JCI112534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. VanDeventer G., Thomson J., Graham L. S., Thomasson D., Meyer J. H. Validation of corrections for errors in collimation during measurement of gastric emptying of nuclide-labeled meals. J Nucl Med. 1983 Mar;24(3):187–196. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES